Wu-yi Sun
China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Nanoparticle-based drug delivery systems: A promising approach for the treatment of liver fibrosis.
Journal: International journal of pharmaceutics: X
Published: July 07, 2025
β-arrestin2 depletion attenuates autoimmune hepatitis in mice via preventing intestinal barrier disruption and inhibiting ERS mediated intestinal epithelial cells apoptosis.
Journal: Biochemical pharmacology
Published: February 14, 2025
SUMO: A new perspective to decipher fibrosis.
Journal: Acta physiologica (Oxford, England)
Published: April 24, 2024
Insight into the regulatory mechanism of β-arrestin2 and its emerging role in diseases.
Journal: British journal of pharmacology
Published: January 15, 2024
Angiotensin II type-2 receptor signaling facilitates liver injury repair and regeneration via inactivation of Hippo pathway.
Journal: Acta pharmacologica Sinica
Published: September 17, 2023
CP-25 exerts a protective effect against ConA-induced hepatitis via regulating inflammation and immune response.
Journal: Frontiers in pharmacology
Published: September 11, 2022
G Protein-Coupled Receptor Kinase 2 as Novel Therapeutic Target in Fibrotic Diseases.
Journal: Frontiers in immunology
Published: November 25, 2021
β-arrestin2 regulating β2-adrenergic receptor signaling in hepatic stellate cells contributes to hepatocellular carcinoma progression.
Journal: Journal of Cancer
Published: February 10, 2021
Inflammasome as an Effective Platform for Fibrosis Therapy.
Journal: Journal of inflammation research
Published: January 28, 2021
Deficiency of β-arrestin2 exacerbates inflammatory arthritis by facilitating plasma cell formation.
Journal: Acta pharmacologica Sinica
Published: May 15, 2020
β-arrestin2 deficiency protects against hepatic fibrosis in mice and prevents synthesis of extracellular matrix.
Journal: Cell death & disease
Published: December 10, 2019
Last Updated: 09/26/2026